Myocarditis Risk Assessment (ESC Criteria)
Identifies suspected myocarditis using ESC 2013 diagnostic criteria. Guides CMR, endomyocardial biopsy, and activity restriction.
Score interpretation
→ Consider alternative diagnosis; repeat troponin; exercise ECG if chest pain; discharge with GP follow-up
→ CMR scan within 1-2 weeks; activity restriction (no sport for 3-6 months); heart failure therapy if LVEF reduced; arrhythmia monitoring; cardiology outpatient
→ Hospital admission; continuous cardiac monitoring; echocardiogram; consider endomyocardial biopsy if fulminant/unclear aetiology; immunosuppression if autoimmune confirmed; PICU if haemodynamically compromised
Interpretation bands for the Myocarditis Assessment. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Metoprolol (IV/Oral — Cardiology) · Beta-Blocker
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.